CRISPR PCSK9 editing delivers 12-month LDL drop in early human trial

The trial used an adenine base editor delivered by lipid nanoparticle to introduce a loss-of-function mutation in PCSK9. Investigators measured LDL-C at baseline, 28 days, 6 months, and 12 months alongside safety labs and off-target sequencing. Mean reduction reached 46% at 12 months with no serious adverse events and durable editing confirmed by circulating biomarkers. This approach bypasses daily statins or PCSK9 monoclonal antibodies that require repeated dosing. Related work in NEJM 2023 on VERVE-101 showed transient editing signals; the current data extend durability but remain limited by small sample size and short follow-up relative to lifetime cardiovascular risk. Regulatory precedent from Casgevy informs manufacturing and delivery standards yet does not address hepatocyte-specific long-term genotoxicity. Next steps require a 300-patient phase 2 trial powered for major adverse cardiovascular events over 3 years with prespecified subgroup analysis by baseline LDL and editing efficiency. Observational cohorts such as UK Biobank PCSK9 loss-of-function carriers provide the comparator for expected event reduction.